# Trastuzumab

## Herceptin inj 440mg

| TAH Drug Code      | [IHER](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IHER)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Herceptin should be used in patients with HER2 overexpression or HER2 gene amplification in the following conditions: 1. Early Breast Cancer (EBC) (1) As adjuvant therapy after surgery and chemotherapy (preoperative or postoperative). (2) As adjuvant therapy following doxorubicin and cyclophosphamide treatment， in combination with paclitaxel or docetaxel. (3) As adjuvant therapy in combination with docetaxel and carboplatin. (4) In combination with chemotherapy as neoadjuvant therapy and as adjuvant therapy after surgery for the treatment of locally advanced (including inflammatory) breast cancer or tumors with a diameter >2 cm. 2. Metastatic Breast Cancer (MBC) (1) As monotherapy for metastatic breast cancer patients who have received at least one prior chemotherapy regimen; prior chemotherapy should have included anthracycline or taxane unless the patient is unsuitable for these treatments. It is also indicated for patients with hormone receptor-positive disease after the failure of hormonal therapy， unless hormonal therapy is unsuitable. (2) In combination with paclitaxel or docetaxel for metastatic breast cancer in patients who have not received prior chemotherapy. (3) In combination with an aromatase inhibitor for hormone receptor-positive metastatic breast cancer. 3. Metastatic Gastric Cancer (mGC) Herceptin， in combination with capecitabine (or 5-fluorouracil) and cisplatin， is indicated for the treatment of HER2-overexpressing metastatic adenocarcinoma of the stomach or gastroesophageal junction in patients who have not received prior chemotherapy. |
| Dosing             | [Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion， then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks， or initial dose of 8 mg/kg over 90 minutes IV infusion， then 6 mg/kg over 30 - 90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion， followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | Patients with known hypersensitivity to trastuzumab or to any other component of Herceptin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Abdominal pain， accidental injury， asthenia， back pain， chest pain， chills， fever， flu syndrome， headache， infection， neck pain， vasodilation， GI disturbances， peripheral edema， edema， arthralgia， myalgia， anxiety， depression， dizziness， insomnia， paresthesia， somnolence， asthma， cough increased， dyspnea， epistaxis， lung disorders， pleural effusion， pharyngitis， rhinitis， sinusitis， pruritus， rash. Cardiovascular: Edema (8% monotherapy )， Peripheral edema (5% to 10% )， Tachycardia (5% monotherapy ) Dermatologic: Rash (4% to 18% ) Gastrointestinal: Abdominal pain (2% to 22% )， Diarrhea (7% to 25% monotherapy; 1.6% grade 3/5 adjuvant therapy )， Loss of appetite (14% monotherapy )， Nausea (6% to 33% )， Vomiting (3.5% to 23% ) Hematologic: Anemia (4% )， Febrile neutropenia (23% adjuvant therapy )， Leukopenia (3% )， Neutropenia (32% grade 3/4; 2% grade 4/5 ) Immunologic: Infectious disease (20% monotherapy; 22% grade 2/5 adjuvant therapy ) Musculoskeletal: Backache (5% to 22% )， Myalgia (4% to 10% ) Neurologic: Asthenia (4.5% to 42% )， Dizziness (4% to 13% )， Headache (6% to 26% )， Insomnia (14% monotherapy; 3.7% grade 2/5 adjuvant therapy ) Respiratory: Cough (2% to 26% )， Dyspnea (3% to 22% )， Pharyngitis (12% monotherapy )， Rhinitis (2% to 14% ) Other: Fever (6% to 36% )                                                                                                                                                                                                                                                         |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| More Info          | [UpToDate](https://www.uptodate.com/contents/trastuzumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## HERCEPTIN inj 600mg/5mL

| TAH Drug Code      | [IHER6](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IHER6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Herceptin should be used in patients with HER2 overexpression or HER2 gene amplification in the following conditions: 1. Early Breast Cancer (EBC) (1) As adjuvant therapy after surgery and chemotherapy (preoperative or postoperative). (2) As adjuvant therapy following doxorubicin and cyclophosphamide treatment， in combination with paclitaxel or docetaxel. (3) As adjuvant therapy in combination with docetaxel and carboplatin. (4) In combination with chemotherapy as neoadjuvant therapy and as adjuvant therapy after surgery for the treatment of locally advanced (including inflammatory) breast cancer or tumors with a diameter >2 cm. 2. Metastatic Breast Cancer (MBC) (1) As monotherapy for metastatic breast cancer patients who have received at least one prior chemotherapy regimen; prior chemotherapy should have included anthracycline or taxane unless the patient is unsuitable for these treatments. It is also indicated for patients with hormone receptor-positive disease after the failure of hormonal therapy， unless hormonal therapy is unsuitable. (2) In combination with paclitaxel or docetaxel for metastatic breast cancer in patients who have not received prior chemotherapy. (3) In combination with an aromatase inhibitor for hormone receptor-positive metastatic breast cancer. |
| Dosing             | 600 mg (600 mg trastuzumab and 10，000 units hyaluronidase) administered subcutaneously over approximately 2-5 minutes once every 3 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Hypersensitivity to trastuzumab， Chinese hamster ovary (CHO) cell proteins， or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | >10%: Cardiovascular: Decreased left ventricular ejection fraction (4% to 22%) Central nervous system: Pain (47%)， chills (5% to 32%)， headache (10% to 26%)， insomnia (14%)， dizziness (4% to 13%) Dermatologic: Skin rash (4% to 18%) Gastrointestinal: Nausea (6% to 33%)， diarrhea (7% to 25%)， vomiting (4% to 23%)， abdominal pain (2% to 22%)， anorexia (14%) Infection: Infection (20%) Neuromuscular & skeletal: Weakness (4% to 42%)， back pain (5% to 22%) Respiratory: Cough (5% to 26%)， dyspnea (3% to 22%)， rhinitis (2% to 14%)， pharyngitis (12%) Miscellaneous: Infusion related reaction (21% to 40%， chills and fever most common; severe: 1%)， fever (6% to 36%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| More Info          | [UpToDate](https://www.uptodate.com/contents/trastuzumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

## Ogivri inj 440 mg (健保)

| TAH Drug Code      | [IOGI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IOGI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Ogivri should be used in patients with HER2 overexpression or HER2 gene amplification in the following conditions: 1. Early Breast Cancer (EBC) (1) As adjuvant therapy after surgery and chemotherapy (preoperative or postoperative). (2) As adjuvant therapy following doxorubicin and cyclophosphamide treatment， in combination with paclitaxel or docetaxel. (3) As adjuvant therapy in combination with docetaxel and carboplatin. (4) In combination with chemotherapy as neoadjuvant therapy and as adjuvant therapy after surgery for the treatment of locally advanced (including inflammatory) breast cancer or tumors with a diameter >2 cm. 2. Metastatic Breast Cancer (MBC) (1) As monotherapy for metastatic breast cancer patients who have received at least one prior chemotherapy regimen; prior chemotherapy should have included anthracycline or taxane unless the patient is unsuitable for these treatments. It is also indicated for patients with hormone receptor-positive disease after the failure of hormonal therapy， unless hormonal therapy is unsuitable. (2) In combination with paclitaxel or docetaxel for metastatic breast cancer in patients who have not received prior chemotherapy. (3) In combination with an aromatase inhibitor for hormone receptor-positive metastatic breast cancer. 3. Metastatic Gastric Cancer (mGC) Ogivri， in combination with capecitabine (or 5-fluorouracil) and cisplatin， is indicated for the treatment of HER2-overexpressing metastatic adenocarcinoma of the stomach or gastroesophageal junction in patients who have not received prior chemotherapy.                                                                                                                                                                                                                  |
| Dosing             | [Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion， then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks， or initial dose of 8 mg/kg over 90 minutes IV infusion， then 6 mg/kg over 30 - 90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion， followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Patients with known hypersensitivity to trastuzumab or to any other component of Ogivri.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Adverse Effects    | Common Dermatologic: Rash (Adjuvant breast cancer， 4%; metastatic breast cancer， 18% to 38% ) Endocrine metabolic: Weight decreased (23% ) Gastrointestinal: Diarrhea (7% to 51% )， Nausea (Adjuvant breast cancer， 6%; metastatic breast cancer， 33% to 76% )， Stomatitis (24% )， Vomiting (Adjuvant breast cancer， 3.5%; metastatic breast cancer， 23% to 53% ) Hematologic: Anemia， All Grades (4% to 36% )， Neutropenia， All Grades (Breast cancer， 6.4%; gastric cancer， 78% )， Thrombocytopenia， All Grades (16% ) Immunologic: Infectious disease (20% to 47% ) Neurologic: Headache (Adjuvant breast cancer， 6.2% to 10%; metastatic breast cancer， 26% to 44% )， Insomnia (Adjuvant breast cancer， 4.3%; metastatic breast cancer， 14% to 29% ) Respiratory: Cough (Adjuvant breast cancer， 5%; metastatic breast cancer， 26% to 43% ) Other: Fatigue (29.5% to 35% )， Fever (Adjuvant breast cancer， 6%; metastatic breast cancer， 36% to 56%; gastric cancer， 18% )， Shivering (Adjuvant breast cancer， 5%; metastatic breast cancer， 32% to 41% ) Serious Cardiovascular: Cardiac dysrhythmia (3% )， Heart failure (Adjuvant breast cancer， 0.4% to 3.2%; metastatic breast cancer， 7% to 28% )， Left ventricular cardiac dysfunction (5% to 18.5% )， Myocardial ischemia， Grade 3 or 4 Hematologic: Febrile neutropenia (23% )， Neutropenia， Grade 3 or 4 (32% to 34% )， Thrombocytopenia， Grade 3 or 4 (5% )， Thrombosis (2.1% to 3.7% ) Immunologic: Hypersensitivity reaction (0.6% to 8% ) Renal: Renal failure Respiratory: Dyspnea (Adjuvant breast cancer， 2.4% to 11.8%; metastatic breast cancer， 22% to 42% )， Interstitial pneumonia， acute (0.2% to 0.7% )， Pulmonary hypertension (0.2% )， Pulmonary toxicity (14.3% ) Other: Infusion reaction (21% to 40% )， Tumor lysis syndrome |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| More Info          | [UpToDate](https://www.uptodate.com/contents/trastuzumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

## Ogivri inj 440 mg (絕對自費)

| TAH Drug Code      | [IOGIS](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IOGIS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Ogivri should be used in patients with HER2 overexpression or HER2 gene amplification in the following conditions: 1. Early Breast Cancer (EBC) (1) As adjuvant therapy after surgery and chemotherapy (preoperative or postoperative). (2) As adjuvant therapy following doxorubicin and cyclophosphamide treatment， in combination with paclitaxel or docetaxel. (3) As adjuvant therapy in combination with docetaxel and carboplatin. (4) In combination with chemotherapy as neoadjuvant therapy and as adjuvant therapy after surgery for the treatment of locally advanced (including inflammatory) breast cancer or tumors with a diameter >2 cm. 2. Metastatic Breast Cancer (MBC) (1) As monotherapy for metastatic breast cancer patients who have received at least one prior chemotherapy regimen; prior chemotherapy should have included anthracycline or taxane unless the patient is unsuitable for these treatments. It is also indicated for patients with hormone receptor-positive disease after the failure of hormonal therapy， unless hormonal therapy is unsuitable. (2) In combination with paclitaxel or docetaxel for metastatic breast cancer in patients who have not received prior chemotherapy. (3) In combination with an aromatase inhibitor for hormone receptor-positive metastatic breast cancer. 3. Metastatic Gastric Cancer (mGC) Ogivri， in combination with capecitabine (or 5-fluorouracil) and cisplatin， is indicated for the treatment of HER2-overexpressing metastatic adenocarcinoma of the stomach or gastroesophageal junction in patients who have not received prior chemotherapy.                                                                                                                                                                                                                  |
| Dosing             | [Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion， then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks， or initial dose of 8 mg/kg over 90 minutes IV infusion， then 6 mg/kg over 30 - 90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion， followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Patients with known hypersensitivity to trastuzumab or to any other component of Ogivri.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Adverse Effects    | Common Dermatologic: Rash (Adjuvant breast cancer， 4%; metastatic breast cancer， 18% to 38% ) Endocrine metabolic: Weight decreased (23% ) Gastrointestinal: Diarrhea (7% to 51% )， Nausea (Adjuvant breast cancer， 6%; metastatic breast cancer， 33% to 76% )， Stomatitis (24% )， Vomiting (Adjuvant breast cancer， 3.5%; metastatic breast cancer， 23% to 53% ) Hematologic: Anemia， All Grades (4% to 36% )， Neutropenia， All Grades (Breast cancer， 6.4%; gastric cancer， 78% )， Thrombocytopenia， All Grades (16% ) Immunologic: Infectious disease (20% to 47% ) Neurologic: Headache (Adjuvant breast cancer， 6.2% to 10%; metastatic breast cancer， 26% to 44% )， Insomnia (Adjuvant breast cancer， 4.3%; metastatic breast cancer， 14% to 29% ) Respiratory: Cough (Adjuvant breast cancer， 5%; metastatic breast cancer， 26% to 43% ) Other: Fatigue (29.5% to 35% )， Fever (Adjuvant breast cancer， 6%; metastatic breast cancer， 36% to 56%; gastric cancer， 18% )， Shivering (Adjuvant breast cancer， 5%; metastatic breast cancer， 32% to 41% ) Serious Cardiovascular: Cardiac dysrhythmia (3% )， Heart failure (Adjuvant breast cancer， 0.4% to 3.2%; metastatic breast cancer， 7% to 28% )， Left ventricular cardiac dysfunction (5% to 18.5% )， Myocardial ischemia， Grade 3 or 4 Hematologic: Febrile neutropenia (23% )， Neutropenia， Grade 3 or 4 (32% to 34% )， Thrombocytopenia， Grade 3 or 4 (5% )， Thrombosis (2.1% to 3.7% ) Immunologic: Hypersensitivity reaction (0.6% to 8% ) Renal: Renal failure Respiratory: Dyspnea (Adjuvant breast cancer， 2.4% to 11.8%; metastatic breast cancer， 22% to 42% )， Interstitial pneumonia， acute (0.2% to 0.7% )， Pulmonary hypertension (0.2% )， Pulmonary toxicity (14.3% ) Other: Infusion reaction (21% to 40% )， Tumor lysis syndrome |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| More Info          | [UpToDate](https://www.uptodate.com/contents/trastuzumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

